{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/634549cdd950350012c90fc5/6af30fd5268f0de56a66a39a?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Current evidence supporting obecabtagene autoleucel in lupus ","description":"<p>The Lupus Hub was pleased to speak with David Jayne, University of Cambridge, UK. We asked, What is the current evidence supporting obecabtagene autoleucel for the treatment of lupus, and what clinical trials are ongoing? </p><p><br></p><p>During this interview, Jayne discussed the scientific rationale and emerging clinical evidence supporting CD19-directed CAR T-cell therapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN). He highlighted the preliminary safety and efficacy data for obecabtagene autoleucel (obe-cel), ongoing clinical trials, and the opportunities and challenges associated with integrating CAR T-cell therapy into routine care. </p><p><br></p><p>Intended for healthcare professionals. This educational resource is independently supported by Autolus. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence. </p>","author_name":"Scientific Education Support"}